Drug Landscape ›
tamsulosin HCl ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 3,936
Most-reported reactions
Fatigue — 549 reports (13.95%) Diarrhoea — 502 reports (12.75%) Death — 422 reports (10.72%) Dizziness — 397 reports (10.09%) Drug Ineffective — 397 reports (10.09%) Dyspnoea — 387 reports (9.83%) Asthenia — 357 reports (9.07%) Fall — 320 reports (8.13%) Pneumonia — 310 reports (7.88%) Nausea — 295 reports (7.49%)
Source database →
tamsulosin HCl in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is tamsulosin HCl approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for tamsulosin HCl in United States?
Boehringer Ingelheim is the originator. The local marketing authorisation holder may differ — check the official source linked above.